Zhongshan, Guangdong-based Akeso Pharmaceuticals obtained its first investigative new drug (IND) application approval from the US FDA on April 2 for its lead asset, AK104, a PD-1/CTLA-4 bispecific antibody.
China Unbound: Second In A Series
China has seen explosive growth in developing new drugs ranging from antibodies to cell therapies, hence the first report from a new series covering emerging biotechs in China. They range from anti-cancer developers to respiratory specialty firms, from Shanghai to Zhongshan – several made-in-China biopharma innovators that largely have been flying under the radar.
See the first article in this series here: Hepalink-Backed HighTide Bets On NASH For Global Markets






